Primera bags $11m in series A:
This article was originally published in Clinica
Developer of gene expression analysis systems and assays Primera Biosystems has raised $11m in a series A financing round. Investors in the Providence, Rhode Island firm include MPM Capital, Burrill and Company and the Malaysian Technology Development Corporation. Primera said the funds will enable it to develop products based on its proprietary STAR (scalable transcription analysis routine) technology, which combines real-time PCR and DNA microarray technologies in one single system.
You may also be interested in...
Two physicians experienced in agency affairs and operations, former commissioner David Kessler and former principal deputy commissioner Joshua Sharfstein, are reportedly finalists to head Biden’s FDA.
Operation Warp Speed will hold back initial shipments to ensure two-dose regimens can be completed; 15 December is ‘chalk’ target date for emergency authorization of Pfizer vaccine, OWS’ Gustave Perna says, calling it only a projection that does not impinge on FDA authority. Sending only half shipments also eases burden on cold shortage capacity at state and local level, he says.
CMS acknowledges stakeholders may need more details about the plan before it is finalized and a delay will give the agency more time to ‘consider the issue.’